右旋糖酐_LOW_右旋糖酐静脉注射Dextran说明书
[caption id="attachment_38411" align="alignleft" width="300"]
LOW MOLECULAR DEXTRAN L INJECTION（右旋糖酐静脉注射）[/caption] 药店国别： 产地国家：日本 处 方 药：是 所属类别：500毫升 20包/盒 包装规格：500毫升 20包/盒 计价单位：盒 生产厂家中文参考译名:大冢制药 生产厂家英文名:Otsuka Pharmaceutical 原产地英文商品名:LOW MOLECULAR DEXTRAN L INJECTION 500ml/bag 20bag/box 原产地英文药品名:Dextran 中文参考商品译名:LMD注射剂 500毫升 20包/盒 中文参考药品译名:右旋糖酐 简介： 部份中文右旋糖酐处方资料(仅供参考) 治疗类别名称： 血浆增容，体外循环灌注溶液(低分子量葡聚糖乳酸林格氏液) 商标名：LOW MOLECULAR DEXTRAN L INJECTION 分子量：約40,000(平均分子量) 性状： 在白色非晶体粉末，没有气味和味道。乙醇(95)或在乙醚中几乎不溶。逐渐溶解在水中。它是吸湿性的。 操作注意事项： 1.一种用于局部富集由于贮存期间温度变化，这可能是很少沉淀不溶葡聚糖(鳞片状或缩合物)。 2.如果看到不溶性葡聚糖的沉淀，你不要用这个。 3.为了防止此类情况的发生，可以存储在下面的章节“存储”。 4.针点刺直东西○橡胶塞的标志。通过在容器颈部角刺注射针，可以是泄漏的原因。 5.软袋产品不能使用的连接管原理串联系统施用。 6.东西和内容液态水滴被发现是不希望使用被着色或在包装浑浊的之一。 7.容器的液体分至被用作粗略指导。 存储(储存条件)： 在室温下储存。但是，为了防止不溶性葡聚糖的沉淀，要注意以下几点。 (1)它被存储在与小温度变化的地方。 例如，冷却器等的出口附近时，应在该温度变化的显著位置避免存储。 (2)不溶性葡聚糖，橡胶塞和容器的软袋内壁和附近7俯卧槽的接触)，沉淀尝试在横向载荷的状态保存。 (3)以降低温度变化的影响，其包围软袋外袋优选为未打开。 适应病： 急性出血的治疗作为血浆代用品，特别是有效的急性大量出血的情况下，初始治疗 创伤，烧伤，基于这样的手术出血休克的预防和治疗 在手术时输血量的储蓄： 它用作体外循环灌注溶液，以减少手术期间的并发症的危险性，以促进灌注。 用法用量： 静脉注射一次500毫升慢。 此外，年龄，体重，适当增加或根据状况减少。 当用作体外循环灌注溶液用于注入2〜3G(20〜30毫升)，为每右旋糖酐40公斤体重。 包装规格： 250毫升含20袋软袋 500毫升含20袋软袋 制造厂商：大冢制药有限公司 Therapeutic category name Plasma expanders, extracorporeal circulation perfusion solution (low-molecular-weight dextran lactated Ringer's solution) Brand Name Low molecular weight dextran L Note (500mL bag) composition The agent is injected solution containing the following ingredients in a first container (500 mL). Dextran 40 50g Calcium chloride hydrate 0.1g Potassium chloride 0.15g Sodium chloride 3.0g L- lactic acid sodium 1.55g Electrolyte concentration Na + 130mEq / L K + 4mEq / L Ca2 + 3mEq / L Cl- 109mEq / L L-Lactate- 28mEq / L This drug contains hydrochloric acid (pH adjusting agent) as an additive. Contraindication From increasing the patient [circulating blood volume with congestive heart failure, placing a burden on the heart, there is a possibility that the symptoms worse. ] Patient [symptoms of hyperlactatemia is likely to be worse. ] Efficacy or effect The treatment of acute bleeding as a blood plasma substitute, particularly effective as initial treatment in the case of acute massive bleeding Trauma, burns, prevention and treatment of surgical shock based on such bleeding Savings of blood transfusion amount at the time of surgery It used as an extracorporeal circulation perfusion solution, to reduce the risk of complications during surgery to facilitate the perfusion. Usually, it injected intravenously once 500mL slowly. In addition, age, body weight, appropriately increased or decreased depending on the condition. When used as an extracorporeal circulation perfusion solution to inject 2~3g (20~30mL) as kg of body weight per dextran 40. To avoid long-term use (kept in as much as possible short-term administration, and within 5 days). Careful administration There is a risk of worsening the patient [renal failure with renal failure. ] There is a risk that the incentive of a patient's state of dehydration [renal dysfunction expression. ] Pulmonary edema of the patient [moisture, electrolyte is retained in the lung cell stroma, there is a possibility that the pulmonary edema is worsening. ] Hypofibrinogenemia, there is a fear that by suppressing the patient [coagulation system with a bleeding tendency, such as thrombocytopenia to promote the bleeding tendency. ] Patient [moisture with severe liver failure, there is a fear that worsen the electrolyte metabolism abnormalities. ] Patient [moisture the amount of urine is reduced by the obstructive urinary tract disease, become the overload of the electrolyte, there is a possibility that the symptoms worse. ] Clinically significant adverse reactions shock (Frequency unknown): Because it may cause shock symptoms, carefully monitored, lowering blood pressure, abnormal heart rate, stop immediately administration if the symptoms such as respiratory depression appeared, to carry out the symptomatic treatment (with dextran 40 injection solution seen side effects: first-order re-eva luation result that 16, 1979). Acute renal failure (Frequency unknown): Since acute renal failure may occur, if an abnormality such as oliguria are observed, discontinue administration, continuous blood filtration dialysis, plasma exchange, to carry out the appropriate treatment of blood dialysis. (Side effects seen in dextran 40 injection solution: first-order re-eva luation result that 13, 1977). Hypersensitivity (Frequency unknown): If hypersensitivity symptoms such as anaphylaxis appeared administration should be discontinued and a symptomatic treatment (voluntary revised, 1993). Pharmacology Plasma expanders action Using the adult dogs, in a repeat of this drug injection operation of blood removal and an equal amount experiments carried out the blood dilution, 5 increase in circulating plasma volume and extracellular fluid volume was observed). Acid-base balance, maintaining the electrolyte balance In DatsuchiNaru dog, this drug for 10% dextran 40 pressurized 5% glucose solution, was suppressed to markedly decrease of acid-base balance disorders and serum electrolyte concentration 6). Physicochemical knowledge of active ingredient Generic name: Dextran 40 Molecular weight: About 40,000 (average molecular weight) In non-crystalline powder of white, there is no smell and taste. Ethanol (95) or practically insoluble in diethyl ether. Gradually dissolved in water. It is hygroscopic.
LOW MOLECULAR DEXTRAN L INJECTION（右旋糖酐静脉注射）[/caption] 药店国别： 产地国家：日本 处 方 药：是 所属类别：500毫升 20包/盒 包装规格：500毫升 20包/盒 计价单位：盒 生产厂家中文参考译名:大冢制药 生产厂家英文名:Otsuka Pharmaceutical 原产地英文商品名:LOW MOLECULAR DEXTRAN L INJECTION 500ml/bag 20bag/box 原产地英文药品名:Dextran 中文参考商品译名:LMD注射剂 500毫升 20包/盒 中文参考药品译名:右旋糖酐 简介： 部份中文右旋糖酐处方资料(仅供参考) 治疗类别名称： 血浆增容，体外循环灌注溶液(低分子量葡聚糖乳酸林格氏液) 商标名：LOW MOLECULAR DEXTRAN L INJECTION 分子量：約40,000(平均分子量) 性状： 在白色非晶体粉末，没有气味和味道。乙醇(95)或在乙醚中几乎不溶。逐渐溶解在水中。它是吸湿性的。 操作注意事项： 1.一种用于局部富集由于贮存期间温度变化，这可能是很少沉淀不溶葡聚糖(鳞片状或缩合物)。 2.如果看到不溶性葡聚糖的沉淀，你不要用这个。 3.为了防止此类情况的发生，可以存储在下面的章节“存储”。 4.针点刺直东西○橡胶塞的标志。通过在容器颈部角刺注射针，可以是泄漏的原因。 5.软袋产品不能使用的连接管原理串联系统施用。 6.东西和内容液态水滴被发现是不希望使用被着色或在包装浑浊的之一。 7.容器的液体分至被用作粗略指导。 存储(储存条件)： 在室温下储存。但是，为了防止不溶性葡聚糖的沉淀，要注意以下几点。 (1)它被存储在与小温度变化的地方。 例如，冷却器等的出口附近时，应在该温度变化的显著位置避免存储。 (2)不溶性葡聚糖，橡胶塞和容器的软袋内壁和附近7俯卧槽的接触)，沉淀尝试在横向载荷的状态保存。 (3)以降低温度变化的影响，其包围软袋外袋优选为未打开。 适应病： 急性出血的治疗作为血浆代用品，特别是有效的急性大量出血的情况下，初始治疗 创伤，烧伤，基于这样的手术出血休克的预防和治疗 在手术时输血量的储蓄： 它用作体外循环灌注溶液，以减少手术期间的并发症的危险性，以促进灌注。 用法用量： 静脉注射一次500毫升慢。 此外，年龄，体重，适当增加或根据状况减少。 当用作体外循环灌注溶液用于注入2〜3G(20〜30毫升)，为每右旋糖酐40公斤体重。 包装规格： 250毫升含20袋软袋 500毫升含20袋软袋 制造厂商：大冢制药有限公司 Therapeutic category name Plasma expanders, extracorporeal circulation perfusion solution (low-molecular-weight dextran lactated Ringer's solution) Brand Name Low molecular weight dextran L Note (500mL bag) composition The agent is injected solution containing the following ingredients in a first container (500 mL). Dextran 40 50g Calcium chloride hydrate 0.1g Potassium chloride 0.15g Sodium chloride 3.0g L- lactic acid sodium 1.55g Electrolyte concentration Na + 130mEq / L K + 4mEq / L Ca2 + 3mEq / L Cl- 109mEq / L L-Lactate- 28mEq / L This drug contains hydrochloric acid (pH adjusting agent) as an additive. Contraindication From increasing the patient [circulating blood volume with congestive heart failure, placing a burden on the heart, there is a possibility that the symptoms worse. ] Patient [symptoms of hyperlactatemia is likely to be worse. ] Efficacy or effect The treatment of acute bleeding as a blood plasma substitute, particularly effective as initial treatment in the case of acute massive bleeding Trauma, burns, prevention and treatment of surgical shock based on such bleeding Savings of blood transfusion amount at the time of surgery It used as an extracorporeal circulation perfusion solution, to reduce the risk of complications during surgery to facilitate the perfusion. Usually, it injected intravenously once 500mL slowly. In addition, age, body weight, appropriately increased or decreased depending on the condition. When used as an extracorporeal circulation perfusion solution to inject 2~3g (20~30mL) as kg of body weight per dextran 40. To avoid long-term use (kept in as much as possible short-term administration, and within 5 days). Careful administration There is a risk of worsening the patient [renal failure with renal failure. ] There is a risk that the incentive of a patient's state of dehydration [renal dysfunction expression. ] Pulmonary edema of the patient [moisture, electrolyte is retained in the lung cell stroma, there is a possibility that the pulmonary edema is worsening. ] Hypofibrinogenemia, there is a fear that by suppressing the patient [coagulation system with a bleeding tendency, such as thrombocytopenia to promote the bleeding tendency. ] Patient [moisture with severe liver failure, there is a fear that worsen the electrolyte metabolism abnormalities. ] Patient [moisture the amount of urine is reduced by the obstructive urinary tract disease, become the overload of the electrolyte, there is a possibility that the symptoms worse. ] Clinically significant adverse reactions shock (Frequency unknown): Because it may cause shock symptoms, carefully monitored, lowering blood pressure, abnormal heart rate, stop immediately administration if the symptoms such as respiratory depression appeared, to carry out the symptomatic treatment (with dextran 40 injection solution seen side effects: first-order re-eva luation result that 16, 1979). Acute renal failure (Frequency unknown): Since acute renal failure may occur, if an abnormality such as oliguria are observed, discontinue administration, continuous blood filtration dialysis, plasma exchange, to carry out the appropriate treatment of blood dialysis. (Side effects seen in dextran 40 injection solution: first-order re-eva luation result that 13, 1977). Hypersensitivity (Frequency unknown): If hypersensitivity symptoms such as anaphylaxis appeared administration should be discontinued and a symptomatic treatment (voluntary revised, 1993). Pharmacology Plasma expanders action Using the adult dogs, in a repeat of this drug injection operation of blood removal and an equal amount experiments carried out the blood dilution, 5 increase in circulating plasma volume and extracellular fluid volume was observed). Acid-base balance, maintaining the electrolyte balance In DatsuchiNaru dog, this drug for 10% dextran 40 pressurized 5% glucose solution, was suppressed to markedly decrease of acid-base balance disorders and serum electrolyte concentration 6). Physicochemical knowledge of active ingredient Generic name: Dextran 40 Molecular weight: About 40,000 (average molecular weight) In non-crystalline powder of white, there is no smell and taste. Ethanol (95) or practically insoluble in diethyl ether. Gradually dissolved in water. It is hygroscopic.
用药温馨提示：当您服用此药物时，需定期接受医疗专业人士的检查，以便随时针对其药效、副作用等情况进行监测。本网站所包含的信息旨在为患者提供帮助，不能代替医学建议和治疗。
药品价格查询,专业药品查询网站,药品说明书查询,药品比价 » 右旋糖酐_LOW_右旋糖酐静脉注射Dextran说明书
药品价格查询,专业药品查询网站,药品说明书查询,药品比价 » 右旋糖酐_LOW_右旋糖酐静脉注射Dextran说明书
